FBD Biologics Limited

The purpose of this trial is to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HCB301 IV infusion in subjects aged 18 years and above with advanced solid tumors and relapsed and refractory classical Hodgkin's lymphoma. Primary objective: To evaluate the safety and tolerability of HCB301; to confirm the MTD and RDE (recommended dose for extension phase). Secondary objective: To explore the PK characteristics of subjects receiving single and repeated administration of HCB301 at different dose levels; to evaluate the initial anti-tumor activity of repeated doses of HCB301 on subjects and the duration of response. Pharmacodynamic objective: To verify the dose-response relationship of HCB301 efficacy and safety variables; to verify potential predictive biomarkers of HCB301 response/clinical outcomes.

Evaluate the safety and tolerability of HCB101 combination therapy; Confirm the MTD or RP2D of HCB101 combination therapy

Primary purpose: To evaluate the safety and tolerability of HCB101 and confirm the MTD Secondary purpose: To explore the PK characteristics of single and repeated doses of HCB101 in subjects at different dose levels; To evaluate the initial anti-tumor activity of repeated doses of HCB101 in subjects and the duration of response; Exploratory purpose: To explore the dose-response relationship of HCB101 efficacy and safety variables; To explore potential predictive biomarkers of HCB101 response/clinical outcomes; To explore the pharmacodynamic response of HCB101.